Autolus Therapeutics plc AUTL
1.17 USD -0.02 (-1.68%)
At closeNov 13, 2026, 6:41 PM EST
1.17 0.00 0.00%
After hours · Nov 13, 6:41 PM ET
1.16 Day range 1.24
1.17 52-week range 2.54
- YTD
- -41.21%
- 1 year
- -8.59%
News
benzinga.com Autolus Therapeutics Presents Longer-Term Follow Up Data From Ongoing CARLYSLE Phase 1 Trial; Data Show Clinically Significant Improvements In SLEDAI-2K Scores And Achievement Of DORIS In Most Patients Despite Severe Disease Activity At Baseline Fonger-term follow up data from the ongoing CARLYSLE trial, a Phase 1 dose confirmation clinical trial of obe-cel in severe refractory systemic lupus erythematosus (srSLE), was presented today during…
globenewswire.com Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 Data show clinically significant improvements in SLEDAI-2K scores and achievement of DORIS in most patients, despite severe disease activity at baseline In 15 patients evaluable for safety, obe-cel…
seekingalpha.com Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call Transcript Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call Transcript
marketbeat.com Autolus Therapeutics Q3 Earnings Call Highlights Autolus Therapeutics NASDAQ: AUTL raised its full-year AUCATZYL sales outlook after third-quarter revenue nearly doubled from a year earlier, as the company reported improved manufacturing margins…
benzinga.com Autolus Therapeutics Q3 2026 Earnings Call Transcript Autolus Therapeutics (NASDAQ:AUTL) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Autolus Therapeutics FY2026 AUCATZYL net product revenue expected to be more than $150.000M Autolus Therapeutics (NASDAQ:AUTL) FY2026 AUCATZYL net product revenue expected to be more than $150.000M.
benzinga.com Autolus Therapeutics Q3 EPS $(0.21) Misses $(0.18) Estimate, Sales $41.238M Beat $39.537M Estimate Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 30 percent increase over losses of…
globenewswire.com Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates Company reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $41.2 million, an increase of 95% year-over-year; now expects full-year 2026 AUCATZYL net product revenue to be at…
globenewswire.com Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference LONDON and GAITHERSBURG, Md., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering…- benzinga.com Autolus Therapeutics To Present Clinical Update Abstracts At American Society of Hematology Meeting, December 12-15 Abstract 4498 – Oral PresentationTitle: What to expect during the first 3 months post obecabtagene autoleucel (obe-cel) infusion in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia…
benzinga.com HC Wainwright & Co. Assumes Autolus Therapeutics at Buy, Announces Price Target of $10 HC Wainwright & Co. analyst Douglas Tsao assumes Autolus Therapeutics (NASDAQ:AUTL) with a Buy rating and announces Price Target of $10.
benzinga.com Autolus Therapeutics Published Abstract Filed TO American College Of Rheumatology Convergence 2026 Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today…
benzinga.com The FDA Grants Regenerative Medicine Advanced Therapy Designation to Autolus Therapeutics' Obecabtagene Autoleucel for Systemic Lupus Erythematosus and Lupus Nephritis The next data update from the Phase 1 CARLYSLE trial in patients with SLE has been submitted for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of…- benzinga.com Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M Est Autolus Therapeutics (NASDAQ:AUTL) affirms FY2026 sales outlook from $140.000 million-$150.000 million to $140.000 million-$150.000 million vs $136.669 million estimate.
- benzinga.com Autolus Therapeutics Q2 EPS $(0.15) Beats $(0.23) Estimate, Sales $45.689M Beat $34.016M Estimate Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 16.67 percent increase over losses…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target HC Wainwright & Co. analyst Emily Bodnar reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding…
benzinga.com CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday Dow Jones index gained 600 points, CNH Industrial rose 16% after reporting better-than-expected Q2 results, other stocks also recording gains.- benzinga.com Autolus Therapeutics Reports Preliminary Q2 AUCATZYL Sales Of ~$45M; Raises FY2026 Sales Guidance From $120M-$135M To $140M-$150M Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-dateFY 2026 sales guidance increased to $140 – $150…
benzinga.com Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HIVE, TE, AUTL, GENI, BRC, BIO, BL, RBLX, ZETA, and D.
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com Service Properties Trust, ConocoPhillips And Other Big Stocks Moving Lower In Monday's Pre-Market Session US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market trading. Other decliners: MGRT, UP, CDZI, LCTX, KEP, AUTL, EOG, ANGX, COP.- benzinga.com Earnings Scheduled For March 27, 2026
benzinga.com Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket 
benzinga.com Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session 
benzinga.com DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday 
benzinga.com Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday 
benzinga.com Abercrombie & Fitch, Titan Machinery, Zoom Communications, Woodward And Other Big Stocks Moving Higher On Tuesday - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Earnings Scheduled For November 12, 2025
- benzinga.com Earnings Scheduled For August 12, 2025
benzinga.com FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.- benzinga.com Earnings Scheduled For May 8, 2025
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Earnings Scheduled For March 20, 2025 - benzinga.com This InterContinental Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
benzinga.com Earnings Scheduled For November 12, 2024 
benzinga.com Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Earnings Scheduled For March 14, 2024 Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
- benzinga.com Earnings Scheduled For November 2, 2023 Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
- benzinga.com Earnings Scheduled For August 3, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
- benzinga.com Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.
- benzinga.com Earnings Scheduled For May 4, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
- benzinga.com Earnings Scheduled For March 7, 2023 Companies Reporting Before The Bell • Cohen & Co (AMEX:COHN) is likely to report earnings for its fourth quarter. • Xtant Medical Holdings (AMEX:XTNT) is expected to report earnings for its fourth…
- benzinga.com Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.
- benzinga.com Earnings Scheduled For November 3, 2022 Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
- benzinga.com Earnings Scheduled For August 4, 2022 Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 269 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 951 companies hit new 52-week lows.